EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Date

Title

File

Times

2021-12-23

NEXT DAY DISCLOSURE RETURN

1293

2021-12-22

NEXT DAY DISCLOSURE RETURN

1363

2021-12-20

NEXT DAY DISCLOSURE RETURN

1246

2021-12-17

NEXT DAY DISCLOSURE RETURN

1301

2021-12-16

NEXT DAY DISCLOSURE RETURN

1286

2021-12-15

NEXT DAY DISCLOSURE RETURN

1284

2021-12-14

NEXT DAY DISCLOSURE RETURN

1333

2021-12-08

NEXT DAY DISCLOSURE RETURN

1317

2021-12-07

NEXT DAY DISCLOSURE RETURN

1327

2021-12-06

NEXT DAY DISCLOSURE RETURN

1297

2021-12-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2021

1232

2021-11-24

NEXT DAY DISCLOSURE RETURN

1369

2021-11-23

NEXT DAY DISCLOSURE RETURN

1317

2021-11-22

NEXT DAY DISCLOSURE RETURN

1330

2021-11-19

NEXT DAY DISCLOSURE RETURN

1373

2021-11-18

NEXT DAY DISCLOSURE RETURN

1331

2021-11-16

NEXT DAY DISCLOSURE RETURN

1330

2021-11-15

NEXT DAY DISCLOSURE RETURN

1360

2021-11-12

NEXT DAY DISCLOSURE RETURN

1392

2021-11-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST VISIT COMPLETED IN A PHASE 3 CLINICAL STUDY IN THE PRC IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

1308

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT